TY - JOUR
T1 - Donor-specific antibody to trans-encoded donor HLA-DQ heterodimer
AU - Habig, Dennis F.
AU - Gaspari, Justine L.
AU - Lokhandwala, Parvez M.
AU - Domen, Ronald E.
AU - Abendroth, Catherine S.
AU - Kadry, Zakiyah
AU - Ghahramani, Nasrollah
AU - Shah, Riaz Ali
AU - Jain, Ashokkumar
AU - Shike, Hiroko
N1 - Funding Information:
Funding support for this study was provided by the Penn State Hershey Medical Center Pathology Department (project number 13-9).
Publisher Copyright:
© 2015 Published by Elsevier Inc. on behalf of American Society for Histocompatibility and Immunogenetics.
PY - 2015
Y1 - 2015
N2 - The majority of de novo donor specific HLA antibodies (DSAs) in transplant patients are directed to HLA-DQ antigens, which consist of a heterodimer of alpha and beta chains. Although a heterodimer can theoretically be cis- or trans-encoded, the sensitizing forms generally appear to be forms. DSA to DQ trans-heterodimer has never been reported. We reviewed 360 post-kidney transplant recipients (transplant: 2002-2013; follow-up: 5.6. ±. 3.3. years). DQ DSA was detected in 46 of 57 patients who developed DSA. DSA specificity was consistent with donor mismatched DQ trans-heterodimers in three patients: DQ2.5 (DQB1*02, DQA1*05), DQ2.3 (DQB1*02, DQA1*03), and DQ4.3 (DQB1*04, DQA1*03). Two of them eventually lost grafts (2 and 5. years later) with allograft nephropathy. In conclusion, post-transplant patients may develop DSA to donor DQ trans-heterodimers. Further studies are warranted to determine the clinical significance of such DSAs.
AB - The majority of de novo donor specific HLA antibodies (DSAs) in transplant patients are directed to HLA-DQ antigens, which consist of a heterodimer of alpha and beta chains. Although a heterodimer can theoretically be cis- or trans-encoded, the sensitizing forms generally appear to be forms. DSA to DQ trans-heterodimer has never been reported. We reviewed 360 post-kidney transplant recipients (transplant: 2002-2013; follow-up: 5.6. ±. 3.3. years). DQ DSA was detected in 46 of 57 patients who developed DSA. DSA specificity was consistent with donor mismatched DQ trans-heterodimers in three patients: DQ2.5 (DQB1*02, DQA1*05), DQ2.3 (DQB1*02, DQA1*03), and DQ4.3 (DQB1*04, DQA1*03). Two of them eventually lost grafts (2 and 5. years later) with allograft nephropathy. In conclusion, post-transplant patients may develop DSA to donor DQ trans-heterodimers. Further studies are warranted to determine the clinical significance of such DSAs.
UR - http://www.scopus.com/inward/record.url?scp=84953349442&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84953349442&partnerID=8YFLogxK
U2 - 10.1016/j.humimm.2015.09.004
DO - 10.1016/j.humimm.2015.09.004
M3 - Article
C2 - 26382246
AN - SCOPUS:84953349442
SN - 0198-8859
VL - 76
SP - 587
EP - 590
JO - Human Immunology
JF - Human Immunology
IS - 8
ER -